Genetic variability in the complement system and its association with disease has been known for more than 50 years, but only during the last decade have we begun to understand how this complement genetic variability contributes to the development of diseases. A number of reports have described important genotype-phenotype correlations that associate particular diseases with genetic variants altering specific aspects of the activation and regulation of the complement system. The detailed functional characterization of some of these genetic variants provided key insights into the pathogenic mechanisms underlying these pathologies, which is facilitating the design of specific anti-complement therapies. Importantly, these analyses have sometimes revealed unknown features of the complement proteins. As a whole, these advances have delineated the functional implications of genetic variability in the complement system, which supports the implementation of a precision medicine approach based on the complement genetic makeup of the patients. Here we provide an overview of rare complement variants and common polymorphisms associated with disease and discuss what we have learned from them.
Introduction
The complement system is a key element of innate immunity. It can trigger alarm signals warning about the presence of pathogens, immune complexes or cell remains. Complement discriminates between our own components and pathogenic ones, tagging the latter for elimination by the cells of the phagocyte system, or for direct destruction through cell lysis. Briefly, the actions of complement include the following processes: i) Complement activation by three independent activation pathways, the classical (CP), lectin (LP) and alternative (AP) pathways, which results in the formation of unstable protease complexes, named C3-convertases (AP, C3bBb; CP/LP, C4b2a) that cleave C3 to generate C3b; ii) Convertase-generated C3b can form more AP C3-convertase, providing exponential amplification of the initial activation; and iii) Clustering of C3b molecules around the surface-bound C3-convertase generates the C5-convertase with the capacity to bind and cleave C5, triggering inflammation and initiating formation of the lytic membrane attack complex (MAC). Several regulatory proteins restrict complement activation to the surface responsible for its activation and restrict consumption after activation. The loss of complement regulation leads to the generation of pro-inflammatory components and/or tissue damage. Both situations have pathologic consequences (Ricklin et al., 2010; de Cordoba et al., 2012; Holers, 2008; Ricklin and Lambris, 2013; Sjoberg et al., 2009) . In this review, we will describe several common and rare complement variants associated with disease to illustrate how their identification and, eventually, their structural and functional study, has been instrumental to understand the roles of complement in disease.
Genetic variability in the components and regulators of the Classical Pathway (CP)
The CP is triggered by antibody-antigen immune complexes via C1q recognition of Fc domains in IgM or IgG. Activation of the CP can also occur independently of antibodies, as C1q can bind directly to certain microbial epitopes, apoptotic or necrotic cells and pattern recognition molecules. Independently of the trigger, CP activation tags the activating surfaces for their removal by phagocytosis and CP progression ultimately leads to the destruction of target cells by the assembly of the MAC.
The C1 complex
The first component of the CP (C1) is a calcium-dependent complex involving three proteins: C1q, C1r and C1s. Under physiologic conditions, the C1 heterotrimer comprises two weakly interacting subunits: C1q, an opsonin containing the binding sites for CP activators, and C1r 2 s 2 , a tetrameric C1s-C1r-C1r-C1s complex with enzymatic activity. Genetic alterations causing deficiency of the C1 complex are strongly associated with the development of autoimmune disease, bacterial infections and the development of glomerulonephritis. The association between C1 complex deficiencies and autoimmunity underlines the fundamental role that the CP has in the elimination of cellular debris; the inability to efficiently clear apoptotic and necrotic cells renders them a source of autoantigens and drives autoantibody production (Navratil et al., 2001 ).
C1q
C1q is a 460 kDa hexameric plasma glycoprotein comprised of 18 peptide chains (6 A, 6B and 6C) arranged in a "bouquet of tulips" disposition. It is a pattern recognition molecule capable of binding to a variety of ligands on microbial surfaces, apoptotic or dying cells and to immune complexes (Kishore and Reid, 2000) . Interaction between C1q and its receptors gC1qR, calreticulin-CD91 and integrin α 2 β 1 , allows clearance of apoptotic cellular debris and triggers subsequent B cell tolerance, macrophage polarization and monocyte-dendritic cell development (Hosszu et al., 2010; Bohlson et al., 2014) . Notably, a number of functions of C1q do not involve classical pathway activation, suggesting that C1q plays additional roles in homeostasis like induction of apoptosis in prostate cancer cells overexpressing WOX1 or induction of angiogenesis during wound healing (Kouser et al., 2015; Hong et al., 2009; Bossi et al., 2014) . C1q has also been implicated in synaptic pruning in the developing CNS, trophoblast invasion, vascular remodelling and normal placentation during pregnancy (Stevens et al., 2007; Singh et al., 2011) .
Approximately 70 cases of congenital C1q deficiency, either antigenic or functional, have been reported associated with rare variants in the C1Q genes (Roumenina et al., 2011) . These C1q deficiencies associate with chronic infections and increased risk of autoimmune pathology, particularly SLE, SLE-like disease and glomerulonephritis (Macedo and Isaac, 2016; Stegert et al., 2015; Botto et al., 1998) . In addition, several C1q polymorphisms have been associated with rheumatoid arthritis (RA), cancer and metabolic or neurolopsychiatric disorders like type 2 diabetes or schizophrenia (Abecasis et al., 2004; Dardiotis et al., 2009; Goulielmos et al., 2013; Mosaad et al., 2015; Petry and Loos, 2005; Racila et al., 2006; Trouw et al., 2013; Xu et al., 2009; Zakharyan et al., 2011; Zervou et al., 2011) .
C1r and C1s
C1r and C1s are the enzymatic components of the C1 complex. They circulate in plasma as zymogens in an extended tetrameric Ca 2+ -dependent complex (C1r 2 s 2; C1s-C1r-C1r-C1s). Upon binding to the collagen-like domains of C1q, the C1s 2 r 2 complex undergoes a conformational change that triggers C1r autoactivation, which in turn converts the C1s zymogen into an active serine protease (Venkatraman Girija et al., 2013; Gaboriaud et al., 2014; Arlaud et al., 2002) . Thirty cases with complete C1r/C1s deficiencies have been described to date. Like C1q deficiencies, they associate with increased risk to autoimmune disease, bacterial infections and glomerulonephritis (Grumach and Kirschfink, 2014) . Notably, heterozygous gain-of-function mutations in C1r or C1s cause type I periodontal Ehlers-Danlos syndrome (P-EDS), an autosomal dominant disease affecting connective tissue integrity. The rare C1r and C1s variants associated with P-EDS involve the subunit interfaces or inter-domain hinges of C1r and C1s, which may increase C1r autoactivation and lead to CP activation on offtarget substrates (Kapferer-Seebacher et al., 2016) . Among the diseaseassociated common C1s variants, there is a polymorphism (rs7311672) that has been reported to confer increased risk for Alzheimer disease (AD) (Jones et al., 2010) .
C1-Inhibitor
C1-Inhibitor (C1INH) is a single chain, highly glycosylated 105 kDa protein containing a long, unique N-terminal domain with no homology in the human genome and a C-terminal SERPIN domain. C1INH irreversibly inhibits proteases from the CP and LP, coagulation, fibrinolysis and contact cascades by forming SDS-stable serpin-protease complexes. In the context of CP regulation, C1INH inhibits the activated C1s, C1r and C2 proteases. C1INH deficiency causes autosomal dominant Hereditary Angioedema (types I and II), a rare disease characterized by spontaneous episodes of edema in the subcutaneous and submucosal layers (Cicardi et al., 2014) .
C4 and C2
C4 is synthesised as a 200 kDa β1-globulin and intracellularly processed into three polypeptide chains (α, β, and γ) with molecular masses of 93 kDa, 78 kDa, and 33 kDa, respectively (Kidmose et al., 2012) . C4 exists as two highly homologous isotypes (C4A, for "acidic" and C4B, for "basic") encoded by two tandem-oriented genes on chromosome 6 (6p.21) and carrying the antigenic determinants corresponding to the Rodgers and Chido blood groups, respectively (Truedsson, 2015) . Upon activation by C1s or MASP2, the α-chain of C4 is cleaved to yield C4a and C4b fragments. The nascent C4b fragments become covalently linked to target surfaces through their reactive thioester sites. The C4A and C4B paralogs share 99% sequence identities but exhibit significant functional differences: C4A most efficiently forms a covalent amide bond with amino group-containing antigens, whereas C4B tends to a form a covalent ester bond with hydroxyl group-containing substrates. Such distinctive functionality between C4A and C4B results in different haemolytic activities, covalent affinities to antigens and serological reactivities (Law et al., 1984; Blanchong et al., 2001 ).
C2, a 83 kDa plasma glycoprotein that circulates in plasma as a zymogen, is organized as a N-terminal portion containing three short consensus repeat (SCR) domains (C2b) and a portion containing a von Willebrand Factor type A domain (vWFA) linked to a C-terminal trypsin-type serine protease domain (C2a) (Mortensen and Jensen, 2016) . Upon binding to C4b, C2 is cleaved by activated C1, which releases the C2b fragment. C2a remains bound to C4b as an active serine protease to form the CP C3/C5 convertases C4b2a and C4b2a3b, respectively.
Homozygous C2 deficiency is relatively common, with an estimated prevalence of 1:10.000 in Caucasians, over 90% of them carrying a common 28-base pair deletion (28BP-Del) (Truedsson, 2015) . Like the C1 complex deficiencies, the complete absence of C2 is associated with SLE or SLE-like disease and, to a lower extent, with bacterial infections, particularly invasive infection by encapsulated bacteria. Polymorphisms in the C2 locus are associated with AMD. Initial analyses indicated that the rs9332739 (E318D) and the rs547154 (intron10) variants of C2, which are in almost complete linkage disequilibrium (LD) with the rs4151667 (L9H) and rs641153 (R32Q) variants in CFB (see below), conferred significant protection against AMD (Gold et al., 2006; Richardson et al., 2009 ). Later on it was shown that these polymorphisms are also protective from polypoidal choroidal vasculopathy (Chen et al., 2015) , but increase the risk for anterior uveitis (Yang et al., 2016) and diabetic retinopathy (Wang et al., 2013) .
The C4 locus is structurally complex as the C4A and C4B genes are part of a larger genetic module known as RCCX, which includes the genes for: STK19 (also known as RP1, a serine/threonine protein kinase), complement C4A and C4B, CYP21A2 (cytochrome P450 steroid 21-hydroxylase) and TNXB (extracellular matrix protein). Segmental duplications of the RCCX module lead to significant variations in the number of C4 genes. In the general population, the total number of C4A and C4B copies varies between 0 and 8, with 30% of the individuals having lower C4A and/or C4B protein levels due to copy number variations (CNV) . Partial C4 deficiencies are, therefore, relatively common. (Blanchong et al., 2001) . Complete C4 deficiency is rare and strongly associated to SLE, with approximately 80% of individuals exhibiting lupus-like disease, (Hauptmann et al., 1974; Wu et al., 2009a) . Similarly, partial deficiencies of C4, due to homozygous or heterozygous C4A deletions, significantly increase the risk of SLE in Europeans .
Excessive copy numbers of C4A and C4B genes and C4 activity also have pathological consequences. Sekar and colleagues have recently shown that there is a significant relationship between alleles with increased expression of C4A and C4B in the brain and schizophrenia; the linkage being higher for alleles that promoted greater expression of C4A (Sekar et al., 2016) . Since loss of cortical gray matter and abnormally reduced numbers of synaptic structures on cortical pyramidal neurons is the main pathological finding in schizophrenia brains (Glausier and Lewis, 2013) , and C4 may work with other components of the CP to promote synaptic pruning, the authors suggest that excessive C4 activity may reduce the number of synapses and contribute to the development of schizophrenia (Sekar et al., 2016; Presumey et al., 2017) .
Functional implications and disease associations of genetic variability in the components and regulators of the Lectin Pathway (LP)
The LP is activated upon recognition of pathogen-and danger-associated molecular patterns by the soluble recognition molecules collectins (MBL, CL-10 or CL-L1, CL-11 or CL-K1) and ficolins (-1, -2, -3 also named -M, -L and -H, respectively) (Garred et al., 2016) . Collectins and ficolins share a similar structure, comprising an N-terminal collagen-like domain, followed by a coiled-coil region and a globular Cterminal domain involved in ligand recognition. A single peptide chain assembles into helical trimers that further oligomerize into characteristic bouquet-like structures held together with interchain disulphide bridges (Holmskov et al., 2003) . Following the binding of the recognition molecules to their carbohydrate or acetylated ligands, LPassociated serine proteases (i.e. MASP-1 -2, and -3) become activated. MASP-2 cleaves C4 while both MASP-1 and MASP-2 cleave C2, generating the LP C3 convertase (C4b2a) identical to the CP C3 convertase. MASP-3 activates the alternative pathway component factor D (FD) by cleaving pro-FD to enzymatically-active FD (Garred et al., 2016; Dobo et al., 2016a) .
Pattern recognition molecules (collectins and ficolins)
Collectins are a family of C-type lectins. They recognize conserved carbohydrate residues via their C-terminal carbohydrate recognition domain (CRD). The ability of the collectins to form high order oligomers is critical for their function; the affinity of a single lectin domain towards carbohydrates is weak, thus it requires the increased avidity generated by the oligomerization of the recognition domain (Hakansson and Reid, 2000) . Three collectins have been identified as activators of the LP: MBL, CL-10, and CL-11.
MBL (encoded by the MBL2 gene) is the best characterized LP collectin. MBL deficiency is remarkably common in caucasoid populations, and genetic variants causing altered serum levels have been associated with many diseases. Although the relevance of MBL as a disease-causing Low serum levels (Sumiya et al., 1991; Lipscombe et al., 1992; Madsen et al., 1994 Madsen et al., , 1995 Madsen et al., 1998) (Cedzynski et al., 2007; Hummelshoj et al., 2005) Susceptibility to infections (de Messias-Reason et al., 2009; Assaf et al., 2012; Mishra et al., 2015; Ouf et al., 2012; Xu et al., 2015) rs3124953; rs17514136; rs7851696 Increased serum levels and/or binding (Hummelshoj et al., 2005) Susceptibility to infections (de Messias-Reason et al., 2009; Assaf et al., 2012; Mishra et al., 2015; Ouf et al., 2012; Xu et al., 2015 Early termination; Non-catalytically active; Nonsecreted; Predicted to be deleterious (Munye et al., 2017; Rooryck et al., 2011; Pihl et al., 2017; Atik et al., 2015; Graul-Neumann et al., 2018; Sirmaci et al., 2010; Urquhart et al., 2016; Yongqing et al., 2013 )
Decreased serum levels (Stengaard-Pedersen et al., 2003) Infections and inflammation NA, not applicable.
factor remains debatable (Garred et al., 2006) , decreased MBL levels increase infection susceptibility and are considered an aggravating factor in the development of pathologies such as cystic fibrosis (Garred et al., 1999; Dorfman et al., 2008; Chalmers et al., 2011) and common variable immunodeficiency (Fevang et al., 2005; Andersen et al., 2005) . Low MBL levels also negatively impact kidney graft survival (Bay et al., 2013; Golshayan et al., 2016) . Several SNPs have been identified in the promoter and exons of the MBL2 gene that could explain the high variability observed in MBL serum levels ( Table 1) . Most of that variation can be attributed to the so-called O allele, grouping three distinct SNPs (i.e. alleles B, C, and D) within the MBL2 exon 1. The B allele (c.161 G > A, rs1800450) refers to a Glycine to Aspartic acid substitution predicted to impair the assembly of the triple helix, causing MBL serum levels 10 times lower than wild type (also called A allele) (Sumiya et al., 1991) ; the C allele, a non-synonymous mutation (c.170 G > A, rs1800451) common in the West African population also results in decreased MBL serum levels (Lipscombe et al., 1992) . On the other hand the D allele (c.154C > T, rs148078249), a missense mutation causing an Arginine to Cysteine change is present in Caucasians but virtually absent in West Africans, and was found to cause a more moderate decrease of MBL levels (Madsen et al., 1994) . CL-10 and CL-11, encoded by COLEC10 and COLEC11 respectively, are two highly homologous collectins that mostly circulate in plasma as high molecular weight CL-10/CL-11 heterocomplexes (Bayarri-Olmos et al., 2015; Henriksen et al., 2013) . They display an identical domain distribution and a 47% sequence homology at the amino acid level, but whereas CL-11 is a known activator of the LP , the biological role of CL-10 remains obscure. Recently, exome sequencing studies in 3MC patients (Malpuech, Carnevale, Michels, and Mingarelli syndrome) revealed that several of them carry COLEC10 mutations in homozygosis or compound heterozygosis, which result in complete CL-10 deficiencies (Munye et al., 2017) (Table 1) . Originally described as four separate disorders, the 3MC syndrome is a rare congenital disorder characterized by mental retardation, growth deficiency, and physical abnormalities such as cleft lip, hypertelorism, eyelid dropping, and skeletal malformations (Titomanlio et al., 2005) . The authors found that COLEC10 was expressed in the epithelium and mesenchyme of the jaw and palate in mouse embryos, supporting a role for CL-10 in the development of craniofacial structures by regulating neural crest cell migration and maintaining cell adhesion. Prior to the implication of COLEC10, two other LP genes were associated with the developmental complications observed in 3MC patients: COLEC11 and MASP1. Of interest, mutations in COLEC10, COLEC11, and MASP1 genes account for just 40% of the identified cases of 3MC. COLEC11 is expressed ubiquitously during embryogenesis, where it is also expected to function as a chemoattractant regulating neural crest migration (Rooryck et al., 2011) . As with COLEC10, all 3MC-associated mutations in COLEC11 result in a complete CL-11 deficiency (Table 1) . It is interesting that the deficiency of either CL-10 or CL-11 is sufficient to cause the developmental complications that characterize 3MC, which suggest that the CL-10/CL-11 heterocomplexes may be required for high avidity binding to carbohydrates during embryogenesis.
Three ficolins are present in humans: ficolin-1 (M-ficolin), ficolin-2 (L-ficolin), and ficolin-3 (H-ficolin, Hakata antigen) encoded by the FCN1, FCN2, and FCN3 genes respectively. Ficolin-1 is mainly expressed by monocytes and neutrophils, while ficolin-2 and ficolin-3 are expressed in the liver and secreted into the circulation. Ficolin-1 and -2 share a 79% homology and ficolin-3 is 48% homologous with these at the amino acid level (Garred et al., 2016) . Several SNPs have been reported for all three genes (Garred et al., 2010) , and some are associated with alterations in serum levels and ligand binding. To date, the published evidence suggests a role of ficolins as immune and inflammatory mediators, where low ficolin concentrations renders the host susceptible to microbial infections and high concentrations may trigger inflammatory disorders. FCN1 promoter variants causing lower ficolin-1 concentrations were shown to be protective against development of clinical leprosy (Boldt et al., 2013) , whereas variants causing high ficolin-1 levels were associated with fatal outcome of systemic inflammation (Munthe-Fog et al., 2012) , and risk of rheumatoid arthritis (Vander Cruyssen et al., 2007) . Similarly, decreased ficolin-2 caused by polymorphisms in the FCN2 promoter and non-synonymous mutations in the fibrinogen-like domain have been associated with many different infectious diseases, such as leprosy (de Messias-Reason et al., 2009) , rheumatic fever and chronic rheumatic heart disease, leishmaniasis (Assaf et al., 2012; Mishra et al., 2015) , hepatitis B (Hoang et al., 2011) , schistosomiasis (Ouf et al., 2012) , and tuberculosis (Xu et al., 2015) . The FCN3 gene is very conserved and ficolin-3 deficiency is remarkably rare, with only three cases reported thus far and the contribution of ficolin-3 to susceptibility to recurrent infections still remains to be formally determined (Munthe-Fog et al., 2009 ).
MASPs
Two genes give rise to a total of five MASPs in humans via alternative splicing: MASP1 encodes MASP-1, MASP-3, and the non-enzymatic MAP-1; while MASP2 encodes MASP-2 and the non-enzymatic sMAP. The MASPs share a common structure comprising a heavy chain, involved in the Calcium-dependent binding to the collagen-like stalks of the peptide recognition modules, and a light chain responsible for their protease activity. The heavy chain is composed of two CUB (for complement C1r/C1s, Uegf, Bmp1) domains separated by an EGF domain and followed by two SCR domains, while the light chain contains the serine protease domain.
Deficiencies of MASPs are very rare, though some have been reported. The first MASP-2 deficiency was found in a patient suffering from recurrent infections and chronic inflammatory disease (StengaardPedersen et al., 2003) . Mutations in the MASP1 gene have been reported in families with 3MC syndrome. The large majority of MASP genetic variants are located in an exon coding for the specific serine protease domain of MASP-3 (Table 1 ). Interestingly one of the few exceptions, the c.49 G > T variant (rs746649361) affecting all three MASP1 isoforms, is linked to a non-classical 3MC phenotype (Kari et al., 2017) . By studying the tridimensional structure of the serine protease domain, it becomes apparent that there is mutational hotspot around the catalytic site. With the exception of p.Gly687Arg (rs533236263), all variants destabilize the protein structure leading to intracellular degradation or decreased protein expression (Pihl et al., 2017) .
Regardless of their location, all mutations obliterate MASP-3 activity, thereby reinforcing the thesis that lack of MASP-3 activity is central to the development of the 3MC syndrome. The ramifications of a catalytically defective MASP can be understood by considering the promiscuous activity of the enzymes of the lectin pathway. MASP-1 is known to interact with systems spanning well-beyond the LP, such as coagulation and inflammatory processes (Dobo et al., 2016a) . MASP-3 has recently been proposed as the authentic pro-FD activator in blood (Takahashi et al., 2010; Iwaki et al., 2011; Oroszlan and Kortvely, 2016; Dobo et al., 2016b) , though not without discussion. This is supported in part by the observation that 3MC patients, deficient for MASP-3, show only residual AP activation (Atik et al., 2015; Degn et al., 2012) and their sera contains mostly pro-FD (Pihl et al., 2017) , compatible with the idea that MASP-3 is the main pro-FD activator.
Functional implications and disease associations of genetic variability in the components and regulators of the Alternative Pathway (AP)
The AP provides non-specific activation of the complement system, which is essential to fulfill the role of the complement system as an innate immune defense mechanism. Thus, while activation through the CP and LP focuses C3b deposition at the location of the antigen recognized by the complement activating antibodies or the carbohydrates recognized by the lectin molecules, initiation of the AP is based on the spontaneous (and protease-mediated) activation of C3, which results in nonspecific C3b deposition on all nearby surfaces (Harrison, 2018) . Because this continuous low-level activation of C3 triggers the AP everywhere, the complement system requires regulatory mechanisms to avoid damage to host cells and prevent the consumption of its components. These control mechanisms discriminate between pathogens and host cells so that the activity of complement in fighting microorganisms and removing cellular debris is not compromised. During the last two decades, several rare mutations and common polymorphisms in the proteins of the AP have been described associated with disease and shown to dysregulate the activity of the AP at different levels. These data have provided crucial insights into the pathogenic mechanisms underlying various diseases and have contributed to a better understanding of the structure and function of the AP components.
Rare CFH variants
Factor H (FH), an abundant plasma glycoprotein composed of 20 SCR domains, is the main regulator of the AP in the fluid phase and on cell surfaces. The complement regulatory activities of FH, dissociation of the AP C3/C5 convertases (decay accelerating activity) and enabling Factor I-mediated C3b inactivation (cofactor activity), are located in a region spanning SCR1-4, while the ability of FH to discriminate complement-activating surfaces resides in the regions comprising SCR 6-7 and SCR19-20 . FH distinguishes host cells from pathogens by recognizing self-associated molecular patterns (SAMPs), such as heparin sulphates (HS), glycosaminoglycan (GAG) and sialic acids moieties, which are ubiquitously found on mammalian tissues (Langford-Smith et al., 2015; Varki, 2011) . The composition and distribution of SAMPs influences the interaction of FH with the surface and restricts complement activation to particular sites, protecting others from complement damage (Clark et al., 2011 (Clark et al., , 2013 Ferreira et al., 2013; Makatsori et al., 2001; Varki, 2008) .
Genetic variants causing plasma FH deficiencies have been known for a long time. These variants are distributed through the whole length of the CFH gene and include, missense variants, stop codons, splice mutations and intragenic microdeletions. When they are in homozygosis or compound heterozygosis, they result in FH deficiency leading to complete consumption of C3 in plasma with massive generation of activated C3 products that deposits in the kidney glomeruli causing dense deposit disease, a rare form of C3 glomerulopathy (C3G) characterized by abundant electron dense deposits within the glomerular basement membrane (GBM) (Goodship et al., 2017) . Because complete FH deficiency results in secondary C3 deficiency, opsonophagocytosis is impaired and these patients can be predisposed to infections, particularly by encapsulated bacteria. In heterozygosis, these mutations cause partial FH deficiencies that associate with C3G, but also with a broad spectrum of pathologies with different underlying pathogenic mechanisms, like atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD) and IgA nephropathy (IgAN) (see below), the final pathological outcome being determined by the individual's overall genetic risk to each of these diseases (Rodríguez de Córdoba, 2016) .
A number of disease-associated mutations located in the FH Nterminal region do not cause FH deficiencies as judged by plasma FH levels, although they have similar functional and pathological consequences. Functional analysis of several of these mutants showed reduced binding to C3b which severely impaired cofactor and decay-accelerating activity . Their location in the FH molecule is consistent with our structural understanding, locating the complement regulatory activities in the N-terminus; hence, these mutant FH molecules are unable to regulate complement in plasma and on the cell surfaces (Wu et al., 2009b) (Fig. 1) . Examples of these Nterminal FH variants are: FH c.delK224, a functionally null FH mutant lacking lysine 224 in SCR4 that in homozygosis associates with dense deposit disease (Licht et al., 2006) ; R83S associated with C3G and acquired partial lipodystrophy ; R53H, R78 G and W198R associated with aHUS (Jozsi, 2017; Pechtl et al., 2011) ; D90 G associated with AMD (Yu et al., 2014) .
Missense mutations in the C-terminal region of FH (SCR19-20) that do not alter the levels of FH in plasma are almost exclusively associated with aHUS, a thrombotic microangiopathy that mostly affects the kidneys and that frequently results in terminal renal disease (Goodship et al., 2017) . Functional studies have shown that these aHUS-associated FH mutants adequately regulate complement in plasma (fluid phase), but have limited ability to protect self cells from complement activation. The main learning from this association is that aHUS results from impaired regulation of complement activation on endothelial and other cell surfaces and that the combination of an active complement system in plasma and a defective protection of cell surfaces determines the development of aHUS . Structural studies led by patient mutations have shown that the specific recognition of SAMPs by the SCR19-20 region of FH involves separate sites for Neu5Ac, the main sialic acid variant in humans, and for the TED domain in C3b, iC3b and C3dg (SCR20 and SCR19, respectively) ( Fig. 1) and revealed the critical amino acid residues mediating these interactions (Kajander et al., 2011; Blaum, 2017) . This structural characterization has provided a structural framework that rationalizes the functional consequences of many disease-associated mutations identified in the genetic testing of aHUS patients (Fig. 1) .
R1210C is a remarkable C-terminal FH mutation (Fig. 1 ). It is a highly prevalent mutation that was originally described in association with aHUS, but also confers very high risk of AMD and is associated with C3G (Recalde et al., 2016) . R1210C is, therefore, an exception to the strict genotype-phenotype correlation that characterizes the association of the C-terminal mutations with aHUS. Unique to R1210C is that the cysteine residue introduced by the mutation establishes a disulfide bond with albumin; this mutant FH thus circulates in plasma in complex with albumin (Sanchez-Corral et al., 2002) . This binding to albumin impairs all FH functions (N-and C-terminal), with the result that the mutant FH-R1210C is a functionally null FH molecule. Being R1210C heterozygote is, therefore, equivalent to carrying a partial FH deficiency, known to associate with multiple pathologies with distinct underlying pathogenic mechanisms (Recalde et al., 2016) . In FH-R1210C carriers the final outcome is determined by the individual's overall genetic risk to each of these diseases. One interesting consideration for this highly penetrant CFH mutation in AMD is that it does not impact on the expression or function of FHL-1, which appears to be in conflict with the key role proposed for this CFH alternative spliced product in the pathogenesis of AMD (Clark et al., 2017) .
Common CFH polymorphisms
The Single Nucleotide Polymorphism (SNP) database at the National Center for Biotechnology Information (NCBI) lists hundreds of SNPs in the human CFH gene region (locus Id: 3075), but very few are located in the CFH proximal promoter region or result in an amino acid substitution in the CFH coding sequence. Of interest, however, is the observation that there is very strong linkage disequilibrium (LD) in the CFH genomic region, which reduces genetic variability within this region to combinations of a few SNP-haplotype blocks spanning CFH and the downstream factor H-related genes (CFHR1-5). Among those, haplotypes CFH-H1, CFH-H2, CFH-H3, and CFH-H4, explain more than 90% of the genetic variability at this locus (Fig. 2) .
The CFH-H1 haplotype includes the Tyr402His (rs1061170) polymorphism in SCR7 of FH, which confers strong risk for the development of AMD (Hageman et al., 2005) , the commonest cause of blindness in the western world. AMD is a multifactorial disease, influenced by age, ethnicity and a combination of environmental and genetic risk factors, including a large set of common polymorphisms in complement components and regulators (Seddon, 2017) . Although the pathogenesis of AMD is still unclear, chronic inflammation plays an important role.
Structural studies helped to explain the mechanism by which the 402His allele may impact AMD risk. These studies revealed the presence of a GAG-binding site spanning SCR6-8 and illustrated that the AMD-associated amino acid 402His is directly involved in GAG binding (Prosser et al., 2007) . Switching between histidine and tyrosine at position 402 may alter the ligand specificity of the FH SCR 6-7 domain, resulting in failure to recruit FH to sites in the retina where complement is activated by the accumulation of endogenous compounds such as Creactive protein, HS or Malondialdehyde, involved in the development of AMD (Prosser et al., 2007; Clark et al., 2006 Clark et al., , 2010 Weismann et al., The allele composition at each of these SNPs that characterizes each of the four major extended haplotypes, H1, H2, H3 and H4, is provided and the associated disease risk or disease protection is indicated. (*) The extended haplotype H4 carries the deletion of the CFHR3 and CFHR1 genes, which in homozygosis is strongly associated with the generation of the autoantibodies directed to the C-terminal region of FH that are characteristic of the autoinmune forms of aHUS. 2011). Interestingly, screening for Alzheimer disease-associated genes in Chinese cohorts demonstrated that the FH 402Y allele was associated with higher atrophy rate and more severe cognitive decline .
FH Val62Ile is a common polymorphism in the FH N-terminal region of FH (SCR1) (rs800292) that defines haplotype CFH-H2. The FH 62Ile allele was originally reported to be protective for AMD and later for aHUS and other diseases . Notably, and in contrast with the strong consequences of the rare genetic variations in the N-terminal region of FH mentioned above, the functional impact of the FH-Ile62 variant is subtle and result in 20-50% enhanced activities of FH ). This is not inconsequential because the nature of the complement system and the combination with other variants in complement components and regulators will amplify this small effect and will result in very different AP activities, markedly affecting formation and regulation of the AP C3 convertase in plasma and on cell surfaces, thus influencing the development of disease (see the complotype below).
The haplotype CFH-H3, originally described as a combination of CFH SNPs , has been recently extended to include polymorphisms in the CFHR3 and CFHR1 downstream genes (Abarrategui-Garrido et al., 2009 ). This extended CFH-H3 haplotype strongly associates with risk for aHUS and carries the rs426736 variant that confers protection against meningococcal disease (MD) (Davila et al., 2010) . Analysis of plasma levels of FH and FHR-3 proteins in carriers of this extended haplotype showed slightly reduced levels of FH and 2-fold elevated levels of FHR-3 compared to non-carriers (Bernabéu-Herrero et al., 2015; Pouw et al., 2018) , which may explain the opposite impact of this haplotype in aHUS and MD. The slightly decreased FH plasma levels contributed by CFH-H3 haplotype may predispose to complement dysregulation on the renal endothelial surface in carriers of other pathogenic variants, rationalizing why this haplotype increases risk of aHUS. Identification of the CFH-H3 haplotype has diagnostic value and is used to explain the incomplete penetrance of aHUS among carriers of complement pathogenic variants (Sansbury et al., 2014; Goicoechea de Jorge et al., 2018) .
Neisseria meningitidis recruits FH via the surface lipoprotein fHbp (Schneider et al., 2006; Madico et al., 2006) and it has been shown that FHR-3 competes with FH for binding to fHbp on the bacterial surface, influencing its survival in plasma (Caesar et al., 2014) . Since the ability of N meningitidis to evade the host complement system is determined by the relative levels of FH and FHR-3 on the bacterial surface, the concurrence of decreased FH levels and increased FHR-3 plasma levels may explain the protective effect of the CFH-H3 haplotype against MD (Pouw et al., 2018) .
A common polymorphism in the CFH intron 12 (rs6677604) distinguishes haplotype CFH-H4 and is in strong LD with the deletion of the CFHR1 and CFHR3 downstream genes (Δ CFHR3-CFHR1 ). Δ CFHR3-CFHR1 is a very common polymorphism in humans that strongly associates with protection from AMD, IgAN or C3G and confers elevated risk of SLE (Hughes et al., 2006; Gharavi et al., 2011) , EGdeJ unpublished data) ( Table 2 ). In fact, it has been shown that the prevalence of these diseases in human populations correlates well with the allele frequencies of the Δ CFHR3-CFHR1 polymorphism (Holmes et al., 2013) . In homozygosis, Δ CFHR3-CFHR1 determines the absence of FHR-1. This is a relevant finding in the genetic analysis of aHUS patients that signals the need to search for auto-antibodies against the C-terminal region of FH, the most important acquired factor associated with the development of aHUS in children Dragon-Durey et al., 2009 ) (see also the section addressing the Factor H-related proteins).
Factor I (CFI)
Factor I (FI) is a plasma serine protease involved in the regulation of both the classical and the alternative pathways. It inactivates C3b and C4b in the presence of appropriate cofactors; FH for C3b, C4b-binding protein for C4b and complement receptor 1 (CR1; CD35) or membrane cofactor protein (MCP; CD46), for both C3b and C4b. FI is essential to downregulate the AP of complement activation. Interestingly, partial or complete deficiencies of FI have distinct pathological consequences. Partial FI deficiencies impair proper regulation of C3b which results in excessive AP activation, but does not affect the generation of the C3b breakdown products iC3b and C3dg, which interact with complement receptors CR3 and CR4 to mediate potent proinflammatory responses (Nilsson et al., 2011) . Partial deficiencies of FI, caused by heterozygous loss-of-function mutations in the CFI gene, thus associate with diseases characterized by chronic inflammation or acute complement-mediated tissue damage like AMD, C3G and aHUS. In contrast, complete FI deficiency, resulting from homozygous or compound heterozygous loss-offunction mutations in the CFI gene, causes secondary C3 deficiencies that normally associate with recurrent infections with encapsulated microorganisms (N. meningitides, H. influenzae, S. pneumoniae). Absence of FI results in complete consumption of C3 with massive generation of C3b that cannot be proteolysed to generate iC3b and C3dg, eluding inflammation and tissue damage (Rose et al., 2008) .
Most CFI variants described in the literature are heterozygous rare variants, mainly associated with AMD, aHUS and, occasionally, with different forms of C3G (Seddon et al., 2013; Kavanagh et al., 2015; Osborne et al., 2018) . These variants are distributed along the whole CFI mRNA and affect all structural domains of FI. They are mostly type 2 missense variants, functional consequences of which are normally assessed by evaluating the plasma FI antigenic levels in carriers. In a few CFI variants with normal plasma levels, loss-of function has been established based on functional analysis (Bienaime et al., 2010) .
Notably, no cases of aHUS have been observed among AMD patients carrying CFI variants (Kavanagh et al., 2015) . This is in agreement with the observation described above that carriers of the R1210C CFH variant, which is associated with both aHUS and AMD, never present both pathologies (Recalde et al., 2016) . It is well known that different combinations of common complement polymorphisms confer risk or protect for aHUS and AMD (see below). Therefore, it may be possible that differences in the complement genetic makeup of an individual (complotype) in the context of an appropriate environmental trigger determine the ultimate clinical disease process in a carrier of a partial FI or FH deficiency.
Membrane cofactor protein (MCP; CD46)
CD46 is a type I membrane glycoprotein that regulates both the classical and the alternative pathways by acting as a cofactor in the FImediated inactivation of C3b and C4b deposited on host cells. Rare pathogenic variants and some common polymorphisms in the CD46 gene that decrease the levels of this protein on the cell surfaces or reduce its functional activity have similar consequences to the mutations in the C-terminal region of FH; they do not impact significantly complement regulation in plasma, but have important consequences for the protection of self surfaces from complement damage. This is perhaps the reason why the vast majority of pathogenic CD46 genetic variants described to date have been found in the genetic screening of aHUS patients (Richards et al., 2003; Noris et al., 2003) . Most are present in heterozygosis and are preferentially associated with pediatric cases. Importantly, aHUS carriers of isolated CD46 mutations have better prognosis than carriers of other complement mutations. Systemic sclerosis, miscarriage, HELLP syndrome and C3G are other pathologies in which carriers of CD46 mutations have occasionally been found (Liszewski and Atkinson, 2015) . Most of the known mutations in CD46 are loss of function, either because the mutant protein is not expressed (75% of the cases) or has reduced functional activity (25%).
In a few exceptional cases, CD46 mutations have been found in homozygosis and are associated with unusually severe aHUS presentations, a likely outcome of the complete lack of CD46 on the endothelial surfaces. Some of these homozygote patients also developed common variable Immunodeficiency (CVID) (Fremeaux-Bacchi et al., 2006) , which is consistent with the key role that CD46 plays in the modulation of the adaptive immune responses (Killick et al., 2018) , a consequence of CD46-deficient regulatory T cell failure to promote adequate B cell responses (Fuchs et al., 2009) .
There are several SNPs in the human CD46 gene region, but the very strong linkage disequilibrium between them reduces the genetic variability within this region to few a SNP haplotype blocks spanning the CD46 gene. One of these, the MCPggaac haplotype, is an important risk factor for aHUS, particularly in concurrence with pathogenic gainof-function variants in C3 or CFB (see below) (Esparza-Gordillo et al., 2005; de Jorge et al., 2007; Martínez-Barricarte et al., 2015) . Functional analysis of two SNPs included in this haplotype that are located in the CD46 promoter region suggested a reduced transcriptional activity, which may result in decreased CD46 levels on the cell surface (Esparza-Gordillo et al., 2005) .
C3 and factor B gain of function variants
C3 is the central component and most abundant complement protein. It is composed of two polypeptide chains of 115 and 75 kDa that are organized in 13 domains: an anaphylatoxin domain (ANA; C3a), a small link (LNK) domain, eight homologous macroglobulin domains (MG1-8) forming a ring (MG-ring), a CUB domain connecting this ring with a TED domain that contains a reactive thioester, and the C345C domain (Janssen et al., 2005) . Activation of C3 into C3b causes huge displacement of the TED domain that exposes the reactive thioester to nucleophilic reagents and generates a new surface area containing the binding sites for factor B that are required for AP C3 convertase formation (Gros et al., 2008) FB is a 90 kDa serine protease that circulates as an inactive pro-enzyme in plasma. Three SCRs at the N-terminus comprise the Ba fragment, while a von Willebrand type A domain followed by a serine-protease domain at the C-terminus represent the large Bb fragment. The generation of the AP C3-convertase begins with the interaction between C3b and FB, to form the pro-convertase C3bB. Then a large conformational change occurs in FB, opening its structure and exposing a scissile site that, upon cleavage by FD and release of the Ba fragment, yields the active AP C3-convertase C3bBb (Torreira et al., 2009) .
Rare C3 pathogenic variants causing primary C3 deficiencies are associated with recurrent infections and are well described. Similarly, common polymorphisms in the genes encoding FB and C3 and their association with disease are old discoveries. It was, however, exceptional to encounter genetic variants in the C3 and CFB gene that increased functional activity of the encoded proteins. These C3 and CFB gain-of-function mutations, which result in constitutive activation of the AP, decreasing C3 plasma levels and causing different degrees of hypocomplementemia, have been described in association with aHUS, C3G and AMD (Seddon et al., 2013; de Jorge et al., 2007; FremeauxBacchi et al., 2008; Martinez-Barricarte et al., 2010) .
Gain-of-function FB mutations are characteristic of a subgroup of aHUS patients showing persistent activation of the AP (de Jorge et al., 2007; Roumenina et al., 2009) . Functional characterization of some of them (i.e. D279 G, F286 L, K323E and K350 N) has shown that they enhance formation of the C3bBb convertase or increase its resistance to accelerated decay by complement regulators (de Jorge et al., 2007; Roumenina et al., 2009) . From a pathogenic point of view, it is intriguing that these FB gain-of-function mutations, that mimic C3 nefritic factor (C3Nef) and cause profound complement dysregulation in plasma (Urban et al., 2018) , associate with aHUS. Perhaps this illustrates the need for a second hit to manifest the pathogenic potential of gain-of-function mutations. For example, gain-of-function mutations in FB may require to be combined with impaired surface protection to trigger aHUS (de Jorge et al., 2007) .
Gain-of-function mutations in C3 are associated with aHUS (Martínez-Barricarte et al., 2015; Fremeaux-Bacchi et al., 2008; Schramm et al., 2015 ) C3G (Martinez-Barricarte et al., 2010 Chauvet et al., 2016) and AMD (144). Different experimental approaches have shown that these C3 mutations alter the sensitivity of C3b to inactivation by FH, CR1 and MCP, and change sensitivity of the AP C3 convertase to accelerated decay by FH and DAF (Seddon et 
Loss of FHR-3 and FHR-1 AMD (Hughes et al., 2006) , IgAN (protective) (Gharavi et al., 2011; Tortajada et al., 2017) SLE ( Several unrelated cases described CFH::CFHR3 hybrid gene Substitution of the last C-terminal SCR20 of FH for the whole FHR-3.
aHUS (Francis et al., 2012) Very rare
DupCFHR1
Mutant FHR-1 with SCR123412345 C3G (DDD) Very rare CFHR2::CFHR5 hybrid gene
Hybrid protein containing SCR1-2 of FHR-2 followed by the whole FHR-5 molecule.
C3G (DDD) (Chen et al., 2014) Very rare
CFHR3::CFHR1 hybrid gene
Hybrid protein containing SCR1-2 of FHR-3 followed by the whole FHR-1 molecule.
C3G (C3-GN) (Malik et al., 2012) Very rare
CFHR5::CFHR2 hybrid gene
Hybrid protein containing SCR1-2 of FHR-5 followed by the whole FHR-2 molecule.
C3G (C3-GN) (Xiao et al., 2016) Very rare
DupCFHR5
Mutant FHR-5 with SCR12123456789 C3G (C3-GN) (Gale et al., 2010; Medjeral-Thomas et al., 2014) Several related cases described, 1 unrelated CFHR1::CFHR5 hybrid gene
Hybrid protein containing SCR1-3 of FHR-1 followed by the whole FHR-5 molecule.
C3G (DDD/C3-GN) (Togarsimalemath et al., 2017) Very rare * Due to its generation by non-homologous recombination, it results in loss of CFHR3 and CFHR1. ** If generated by non-homologous recombination, it results in duplication of CFHR3 and CFHR1. *** If generated by gene conversion, the copy numbers of CFHR3 and CFHR1 remains unaltered. Schramm et al., 2015; Chauvet et al., 2016) . Importantly, whilst the C3 mutation associated with C3G affects only regulation by FH and CR1, the aHUS-associated C3 mutations affect primarily cell surface regulation, further supporting the concept that the site of complement dysregulation is critical in the pathogenesis of aHUS and C3G (Rodríguez de Córdoba, 2016) . Two of these C3 gain-of-function mutations associated with aHUS (R161 W and I1147 T) are exceptionally prevalent in Europe and Japan, respectively. The 923delDG mutation associated with C3G is a remarkable C3 gain-of-function mutation that renders C3 resistant to cleavage by the AP C3 convertase . The mutation is a deletion of two amino acids (Asp923, Gly924; 923delDG) in the MG7 domain of C3 that does not alter the normal expression and overall structure of C3. The structural and functional characterization of this mutation helped to determine that a region in the surface of the MG7 domain is a contact surface between the C3 substrate and the C3b molecule in the AP C3 convertase and represents a potential therapeutic target for inhibition of C3 activation (Martinez-Barricarte et al., 2010).
Common C3 and FB polymorphisms; the complotype
The list of complement polymorphisms in C3 and FB associated with disease is large and a detailed description of them out of the scope of this review. There are, however, some of these polymorphisms that deserve special attention as they illustrate the concept of the "complotype": subtle functional alterations in individual complement components that in combination result in significant differences in complement activity.
Two common polymorphisms in LD in the N-terminal region of FB, L9H and R32Q, strongly associate with protection from AMD (Gold et al., 2006) L9H is located in the signal peptide and was suggested to modulate secretion of FB. The R32Q variation reduces the haemolytic activity of FB by decreasing the interaction between the Ba fragment and C3b . These data provide an explanation for the association; the observed protection in each case was ascribed to a reduced activity of the complement AP. Similarly, it has been reported that the C3 polymorphism R102 G increases risk of AMD (Maller et al., 2007) and functional data have revealed that this association is a consequence of increased AP activity of the C3-102 G variant compared to the C3-102R because C3-102 G is more resistant to proteolysis by the complement regulators (Heurich et al., 2011) .
We mentioned earlier that FH Ile62 protects from disease caused by complement dysregulation because it performs better as a complement regulator than FH Val62 . One important conclusion from the functional characterization of this FH polymorphism, and also from the FB Arg32Gln and the C3 R102 G polymorphisms described above, is that whilst the functional alterations caused by these amino acid substitutions are subtle, they are additive and in combination result in very different AP activities, markedly affecting formation and regulation of the AP C3 convertase in plasma and on cell surfaces (Heurich et al., 2011) . Based on these observations it was postulated that the identification of individuals carrying combinations of polymorphisms ('complotypes') in complement components and regulators, which result in high or low AP activity, will be relevant to predict disease risk and perhaps also be of help in diagnosis and choice of treatment for diseases involving complement dysregulation .
Factor D and properdin deficiencies
FD is essential to the AP. It cleaves FB in the C3 proconvertase (C3bB) to generate the active C3 convertase (C3bBb). FD deficiency is an extremely rare autosomal recessive disorder. Individuals with FD deficiency present with increased risk of infections by encapsulated bacteria. Heterozygotes with low FD levels are asymptomatic (Biesma et al., 2001 ).
Properdin is essential to both the AP and the terminal pathway (TP). It stabilizes the C3 and C5 convertases, increasing their life span (Alcorlo et al., 2013) . Properdin deficiency is an X-linked recessive trait with more than 100 cases reported thus far. Mortality from N. meningitidis in individuals with properdin deficiency is very high (Linton and Morgan, 1999) .
The CD55 and CD59 genes
Decay accelerating factor (DAF; CD55) and CD59 are widely expressed glycosylphosphatidylinositol (GPI)-anchored membrane proteins that protect cells against complement-induced self-injury. DAF (CD55) regulates C3 and C5 cleavage by accelerating the decay of the AP C3/C5 convertases. CD59 binds to C8 and C9 and inhibits the final step in the assembly of the membrane attack complex (MAC), which prevents the formation of the osmolytic pore. Although rare, the most common genetic variants associated with alterations of these proteins are somatic mutations of the PIGA gene, which encodes a protein essential for the synthesis of the GPI anchor, leading to the deficiency of all GPI-anchored proteins, CD55 and CD59 included. When this happens in a clonal hematopoietic stem cell, it results in paroxysmal nocturnal hemoglobinuria (PNH), a rare disease that presents with hemolytic anemia, thrombosis and, eventually, bone marrow failure (Hill et al., 2017) . The loss of CD55 and CD59 renders PNH erythrocytes susceptible to intravascular hemolysis, resulting in anemia and a massive release of hemoglobin, which explains the severe thrombophilia that these patients present, responsible for much of the morbidity and mortality of PNH.
Congenital CD55 deficiency is extremely rare and corresponds to the null phenotype of the Cromer blood Group called Inab (Telen et al., 1988) . Interestingly, Inab erythrocytes are largely resistant to reactive lysis, suggesting that the loss of CD59, not CD55, is the cause for the massive intravascular hemolysis that PNH patients suffer. This hypothesis was confirmed with the identification of a founder CD59 mutation (C89Y) in Jewish subjects of North African origin (Nevo et al., 2013) . Homozygous C89Y individuals lack completely CD59 and present massive intravascular hemolysis and thrombophilia, like PNH patients. These individuals, in contrast with PNH patients, lack CD59 in all cells of the organism and present, in addition, with a recurrent peripheral demyelinating disease resembling recurrent Guillain-Barré syndrome or chronic inflammatory demyelinating polyneuropathy. It has been suggested that the TP dysregulation and MAC formation associated with the loss of CD59 causes demyelination in the peripheral nervous system of these patients (Mevorach, 2015) .
Recently, several individuals carrying a complete CD55 deficieny were identified by whole-exome sequencing of patients with gastrointestinal phenotypes, specifically an early-onset protein-losing enteropathy characterized by primary lymphangiectasia, bowel inflammation and thrombotic events (Ozen et al., 2017) . These individuals are homozygote carriers of either frameshift mutations causing premature stop codons or missense mutations that disrupt a critical cysteine residue in the CD55 gene (Ozen et al., 2017; Kurolap et al., 2017) . Although it was shown in vitro that these congenital CD55 deficiencies result in complement over activation on the cell surfaces and these patients respond to complement inhibition with eculizumab, how complement dysregulation distinctively causes the intestinal-tissue damage that results in protein loss is still unclear.
The factor H related proteins (FHRs)
The FHRs are a family of five proteins structurally similar to FH. They are encoded by genes organized in tandem downstream from the FH gene within a region in the RCA gene cluster characterized by strong LD. The FHRs proteins lack the complement regulatory domains of FH but have conserved the FH surface recognition domains in SCR6-8 and SCR19-20, which confers capacity to compete with FH for binding to C3b, iC3b, C3dg, and polyanions like sialic acids, glycosaminoglycans, or heparin on the activating surfaces. A distinctive characteristic of FHR-1, FHR-2, and FHR-5 is that they present an N-terminal dimerization domain. This determines that these FHRs, in contrast to FH, circulate in plasma as heterooligomeric proteins, which increases the avidity for their ligands and facilitates competition with FH (Mihlan et al., 2009; Hakobyan et al., 2008; Okemefuna et al., 2010) . In addition, the FHRs promote complement activation by binding to the extracellular matrix and other complement activating surfaces through interactions with C-reactive protein and pentraxins . Interestingly, a complement regulatory activity at the level of the C5 convertase has been described for FHR-1 (Heinen et al., 2009) , suggesting that FHR-1, depending on the context, may act either as a regulator of the TP or promote complement activation through the AP. Understanding the biological function of the FHR proteins is nowadays an area of intense research activity. The identification of common and rare variants in the FHRs associated with various types of diseases and the functional characterization of some of these variants is an important source of information about their physiological roles.
A number of common and rare CFHRs variants, modifying the plasma levels of the FHRs proteins or introducing subtle functional changes in these molecules, have been described. However, the pathophysiological consequences of most of these variations are unknown. A combination of SNPs in exon 4, 5 and 6 of CFHR1 distinguish two alleles, CFHR1*A and CFHR1*B. CFHR1*A has exon 4 identical to CFH exon 18, which may increase the capacity of this allele to compete with FH. CFHR1*A and CFHR1*B are in LD with the CFH haplotypes CFH-H1 and CFH-H3, which associate with AMD and aHUS, respectively, but the contribution of the CFHR1 alleles to the pathology is still unclear (Abarrategui-Garrido et al., 2009; Martinez-Barricarte et al., 2012) . Similarly, two common variants in CFHR3, c.721C > T (rs379370) and rs426736, included in the CFH-H3 extended haplotype, have been implicated in both increased risk for aHUS (Bernabéu-Herrero et al., 2015) and protection against meningococcal infections (Davila et al., 2010) .
Several variants in CFHR5 have also been associated with aHUS (Westra et al., 2012) , C3G (Abrera-Abeleda et al., 2006; Besbas et al., 2014) and IgAN (Zhai et al., 2016) , although the molecular mechanism by which FHR-5 is involved in the pathogenesis of each disease is again unclear. These variants include both polymorphisms in the promoter region and introns and rare variants in coding sequences. Notably, some of the later are missense mutations resulting in FHR-5 mutant proteins that show an increased C3b binding capacity compared to the wild-type protein (Abrera-Abeleda et al., 2006) , suggesting that CFHR5 gain-offunction mutations, promoting excessive complement activation, contribute to the pathology. In contrast, a heterozygous CFHR5 null mutation has been found in a case of acute poststreptococcal glomerulonephritis , suggesting that reduced plasma levels of FHR-5 is detrimental in the context of infection. So far, CFHR2 and CFHR4 have not been associated with pathological conditions.
Genomic rearrangements involving the CFHRs
The most interesting CFHR1-5 genetic variations associated with disease involve gene rearrangements (Table 2 ). These genomic events are relatively common because the CFH-CFHR region contains large genomic duplications, which makes it highly prone to rearrangements through gene conversion and non-allelic homologous recombination. Rearrangements resulting in the generation of hybrid genes between CFH and CFHR1 or CFHR3 strongly associate with aHUS because they replace the last C-terminal SCR20 of FH by the C-terminal SCR5 of FHR-1, or by the whole of FHR-3, which makes the resulting FH::FHR-1 and (Table 2) . Similarly, the FHR-1::FH hybrid protein in which the C-terminal SCR5 of FHR-1 has been replaced by SCR20 of FH also impairs complement regulation because these FHR-1::FH hybrids compete binding of FH on the endothelium but lack proper complement regulatory activity to substitute for FH Valoti et al., 2015) (Table 2) . When these hybrid genes are generated by gene conversion events, the copy numbers of the CFHR1 and CFHR3 genes remains unaltered. However, if these hybrid genes are the consequence of non-allelic homologous recombination, generation of the FHR-1::FH hybrid also causes duplication of the CFHR3 and CFHR1 genes, while the FH::FHR-1 hybrid results in deletion of the CFHR3 and CFHR1 genes, distinct from the deletion of the Δ CFHR3-CFHR1 allele described above (See CFH-H4 haplotype). A less frequent genomic deletion spanning CFHR1 and CFHR4 (Δ CFHR1-CFHR4 ) has also been identified. Although it has not been associated directly with disease, when present in homozygosis or in compound heterozygosis with the deletion of the Δ CFHR3-CFHR1 allele, it causes complete deficiency of FHR-1 that associates with the generation of anti-FH autoantibodies (Martinez-Barricarte et al., 2010) ( Table 2) .
Notably, there is a set of genomic rearrangements resulting in the duplication of the dimerization domains of FHR-1, FHR-2 and FHR-5, which are specifically associated with C3G, mainly cases of the C3GN subtype (Abarrategui-Garrido et al., 2009; Tortajada et al., 2013; Chen et al., 2014; Gale et al., 2010; Athanasiou et al., 2011; Gale and Pickering, 2011 ) ( Table 2 ). The duplication of the dimerization domain causes abnormal multimerization of FHR-1, FHR-2 and FHR-5, which increases avidity for their ligands and enhances competition with FH Goicoechea de Jorge et al., 2013) . It is postulated that these gain-of-function mutant FHR-1, FHR-2 and FHR-5 proteins are pathogenic because they over-compete FH binding to host surfaces and promote excessive complement activation. A remarkable observation is the very high penetrance of C3G in carriers of these genomic rearrangements. For instance, the internal duplication of exons 2 and 3 in CFHR5 (Dup.CFHR5, Table 2 ), which is characteristic of the CFHR5 nephropathy and very prevalent in Cyprus, has been identified in heterozygosis in more than 90 patients from 16 kindreds and shows a disease penetrance of 90% (Athanasiou et al., 2011) . To explain the high frequency of Dup.CFHR5 in the Cypriot population, researches have postulated a positive allele selection in which the mutation may be a protective factor against rickettsia infections, which are endemic in the island (Kousios, 2017) . Of note, although the Dup.CFHR5 mutation has not been found outside Cyprus, a different genomic rearrangement in CFHR5 leading to the same duplication of SCR1-2 in FHR-5 was found in a UK C3G pedigree without Cypriot ancestry (Medjeral-Thomas et al., 2014) . Much remains to be learned about the role of the FHRs and their association with disease. However, the functional characterization of the proteins resulting from the different CFH/CFHRs rearrangements suggests that the FHRs originated to modulate complement activation by competing FH and promoting complement activation and that these functions can be beneficial or detrimental depending on the circumstances.
Genetic variants in the terminal pathway (TP)
Cleavage of C5 by the C5 convertase initiates the TP, which concludes in the assembly of the membrane attack complex (MAC), an immune pore that mediates cytotoxicity of Neisseria and a wide range of other gram-negative bacteria (Podack, 1984) . Notably, deposition of sublytic levels of MAC on host cells trigger a number of cell signaling pathways including inflammasome activation (Morgan, 2016) and proliferation (Niculescu et al., 1999) . Upon C5 cleavage and C5a release, C5b exposes a labile binding site for C6 that mediates formation of the C5b6 complex. Incorporation of C7 to C5b6 renders the complex lipophilic, driving the release of C5b6 from the C5 convertase and facilitating its insertion into a nearby membrane. The binding of C8 sets the curvature of the pore wall and regulates the binding of C9, the last component of the MAC (de Jorge et al., 2018). The main defense against host-damage by MAC is the GPI-anchored protein CD59 described above.
Congenital deficiencies of the TP components are well described. Generally, these deficiencies lead to increased susceptibility to Neisseria infections (meningococcal sepsis or meningitis and disseminated gonococcal infections). They are not that rare and their prevalence differs greatly between populations. Japan is the country with the highest prevalence of C5, C6, C7, C8 and C9 deficiencies. Common polymorphisms in the TP have been associated with a number of pathologies. Among them are a C9 polymorphism (rs3776519) that has been recently associated with AD (Jones et al., 2010 ) and a C5 polymorphism (Arg885His) which is relatively prevalence in Japanese (3.5%) and Han Chinese populations and has been shown to prevent binding of eculizumab and blockage of C5 activation (Nishimura et al., 2014) .
Clusterin, also known as ApoJ, is a multifunctional molecular chaperone that, together with vitronectin, leads to the formation of MACrelated soluble complexes. This activity is particularly relevant to eliminate off-target MACs that have failed to integrate into a membrane. Three polymorphisms in the CLU gene, rs11136000, rs2279590 and rs9331888 are significantly associated with late-onset Alzheimer Disease (AD) in Caucasians (Harold et al., 2009) , although their relevance in AD pathogenesis is still controversial (Morgan, 2018) .
Genetic variants in complement receptors
CR1 (CD35) is the cell surface receptor for the C3b fragment; CR1 on erythrocytes plays important roles in immune complex transport and phagocytosis of complement-opsonised particles (Ng et al., 1988) . CR1 comprises a long chain of SCRs arranged in long homologous repeats (LHR; each containing 7 SCRs) and shows a peculiar size polymorphism with 4 alleles A, B, C and D, presenting 3, 4, 5 and 6 LHRs, which are also expressed at different levels on the surface of the erythrocytes (Rodriguez de Cordoba and Rubinstein, 1986) . Notably, it has been found that the intensity of complement deposition in PNH-erythrocytes inversely correlates with their expression levels of CR1; individuals carrying the low expression allele CR1-Lare particularly susceptible to extravascular hemolysis under eculizumab treatment (Rondelli et al., 2014; Subias Hidalgo et al., 2017) .
Two common CR1 polymorphisms have been associated with AD; rs4844609 (T1610S) in SCR26, a region reported to be a C1q binding site, and rs6656401, that is in LD with a CR1 length polymorphism that shows reduced CR1 expression (Lambert et al., 2009) . It has been suggested that reduced CR1 expression on erythrocytes leading to impaired amyloid clearance is the mechanism by which the rs6656401 SNP impacts AD pathology (Brubaker et al., 2017) . A similar association with low CR1 expression alleles has been described in preeclamsia (Feinberg et al., 2005) . CR2 (CD21) is a component of the B-cell receptor in mature B cells and follicular dendritic cells. CR2 binds C3d-opsonized immune complexes and enhances antigen-specific B-cell responses. In 2012, the first case of a genetic CR2 deficiency was described (Thiel et al., 2012) . The patient, a 28-year-old man was a compound heterezygote for deleterious mutations in CR2 and presented with recurrent infections, reduced class-switched memory B cells, and hypogammaglobulinemia.
CR3 (CD11b/CD18) binds iC3b and is found on macrophages, neutrophils, and large granular lymphocytes. CR4 (CD11c/CD18) binds iC3b and is found on neutrophils, monocytes, and macrophages. These two receptor proteins and LFA-1 (CD11a/CD18), a very important receptor in cellular adhesion and trafficking, are known as β2 integrins. Inherited deficiency of CR3, CR4 and LFA-1 occur in leukocyte adhesion deficiency type 1 (LAD-1), a rare disease affecting one in 1 million individuals were there is a failure to synthesize CD18 (Shaw et al., 2001 ).
Conclusions
Complement is involved in a long list of diseases, from infection and autoimmunity associated with complement deficiencies, to inflammation and tissue damage caused by excessive complement activation. Notably, the spectrum of complement-related disorders has been recently extended to dysmorphias and neurologic diseases such as Alzheimer's disease or schizophrenia. Although often complement exacerbates the pathological consequences of disease, in some instances it is the primary cause of the pathology by means of genetic variations that alter the activity of the complement components and regulators. A fascinating observation is that the same complement genes are associated with distinct diseases, but particular genetic variants in these genes specifically associate with one disease or another. The functional study of these disease-specific genetic variants is helping to identify pathogenic mechanisms and to guide the development of focused therapies based on the use of complement inhibitors. In addition, it is expected that knowledge about the pathological implications of complement genetic makeup will allow an individualized assessment of disease predisposition, facilitating the implementation of personalized and preventive medicine measures and, in many cases, anticipating the progression of the disease and the patient's response to the different treatments.
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